Stockscreener 앱 받기
0.994
2.47%
0.024
전일 마감가:
$0.97
열려 있는:
$0.99
하루 거래량:
121.10K
Relative Volume:
0.47
시가총액:
$37.54M
수익:
-
순이익/손실:
$-8.82M
주가수익비율:
-3.3133
EPS:
-0.3
순현금흐름:
$-18.01M
1주 성능:
-17.17%
1개월 성능:
-39.02%
6개월 성능:
+17.66%
1년 성능:
-15.19%
1일 변동 폭
$0.99
$1.0499
1주일 범위
$0.9273
$1.211
52주 변동 폭
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.994 | 36.63M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Market Outlook: Will Estrella Immunopharma Inc benefit from government policyJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting By Investing.com - Investing.com South Africa
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting - Investing.com
Estrella Immunopharma Receives Nasdaq Non-Compliance Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView — Track All Markets
Day Trade: What insider trading reveals about Estrella Immunopharma Inc stock2025 Investor Takeaways & Expert Curated Trade Setups - Bộ Nội Vụ
Is Estrella Immunopharma Inc. stock a good choice for value investors2025 Dividend Review & Fast Gain Swing Alerts - Улправда
How Estrella Immunopharma Inc. stock trades during market volatilityWeekly Trend Recap & Safe Entry Trade Reports - ulpravda.ru
How risky is Estrella Immunopharma Inc. stock nowPortfolio Value Summary & Technical Buy Zone Confirmations - ulpravda.ru
Estrella Immunopharma, Inc.Warrant (NQ: ESLAW - FinancialContent
Is Estrella Immunopharma Inc. stock a smart buy before Fed meetingWeekly Volume Report & Long-Term Growth Stock Strategies - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipWatch List & Short-Term Trading Alerts - ulpravda.ru
Is Estrella Immunopharma Inc. stock attractive for passive investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - ulpravda.ru
Published on: 2026-01-07 23:18:22 - Улправда
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - Улправда
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - MEXC
Estrella Immunopharma Signs Multiple Material Agreements - TradingView — Track All Markets
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
Estrella Immunopharma raises $8 million through registered offering By Investing.com - Investing.com Nigeria
Estrella Immunopharma stock falls after announcing $8 million offering - Investing.com India
Estrella Immunopharma raises $8 million through registered offering - Investing.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - The AI Journal
Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5% - MarketBeat
Aug Levels: How Estrella Immunopharma Inc stock reacts to global recession fearsMarket Performance Recap & Low Drawdown Momentum Trade Ideas - Bộ Nội Vụ
Estrella Immunopharma (ESLAW) Stock Analysis Report | Financials & Insights - Benzinga
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma offers up to 2.5 mln shares for resale by selling stockholders - marketscreener.com
Estrella Immunopharma Files for Secondary Offering - marketscreener.com
Investment Review: How interest rate cuts could boost Estrella Immunopharma Inc. stock2025 AllTime Highs & Free Growth Oriented Trading Recommendations - Улправда
Why Estrella Immunopharma Inc. stock remains on buy listsVolume Spike & Free Technical Pattern Based Buy Signals - Улправда
Is Estrella Immunopharma Inc. stock affected by interest rate hikes - Улправда
Is Estrella Immunopharma Inc. stock a safe haven assetEarnings Recap Report & Accurate Buy Signal Alerts - Улправда
Insider Buy: Is Estrella Immunopharma Inc. stock a safe haven asset2025 Breakouts & Breakdowns & High Conviction Buy Zone Picks - Улправда
Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% HigherHere's Why - MarketBeat
Levels Update: How interest rate cuts could boost Estrella Immunopharma Inc. stockWeekly Stock Recap & Verified Swing Trading Watchlists - ulpravda.ru
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Estrella Immunopharma advances STARLIGHT-1 trial after DSMB review - MSN
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView — Track All Markets
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):